DUBLIN, Ireland and PRAGUE, Czech Republic, March 16 /PRNewswire-FirstCall/ -- Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM: AP.L), the Medical Technology Company focussed on the Woundcare, Oralcare and Cardiovascular Health markets today announces the successful development of an effective nano-fibre based delivery platform for its patented m.doc(TM) based woundcare technology.
This month's final haemostasis efficacy studies on m.doc(TM) based nano-fibre woundcare prototypes have proven both effective and efficient haemostasis. This follows nine months of technical evaluation and prototype testing with Alltracel's nanotechnology development partner ELMARCO s.r.o. ("Elmarco") of the Czech Republic.
Manufacturing discussions are now taking place with existing and new manufacturing partners to incorporate this technology into existing and new woundcare delivery systems for both the consumer and professional markets.
Elmarco (www.elmarco.cz) is a specialist R&D and manufacturing company that has developed, in conjunction with the Technical University of Liberic, a novel proprietary & patented process for spinning polymers into nano-scale fibres for a range of industrial, chemical, micro-electronic and bio-medical applications.
Alltracel's CEO, Tony Richardson, commented: "Alltracel has always been committed to innovation and the development of our proprietary m.doc(TM) technology. We are extremely pleased to have worked closely with our development partner Elmarco in undertaking this research which has resulted in a breakthrough in the advancement of nano-fibre delivery systems.
This novel nano-fibre based m.doc(TM) delivery platform enables not only the development of new m.doc(TM) products and delivery systems but also the cost effective re-engineering of existing m.doc(TM) delivery systems.
We are now focussed on manufacturing partnership discussions for both consumer and professional woundcare products and are targeting to have the first m.doc(TM) based nano-fibre products on the market this year."
Notes to Editors:
Alltracel (AIM: AP.L) (www.alltracel.com) Alltracel Pharmaceuticals Plc is a Medical Technology Company focussed on the Woundcare, Oralcare and Cardiovascular Health markets.
With corporate headquarters in Dublin, Ireland; Alltracel has a commercial office in London, England; R&D subsidiary in the Czech Republic and manufacturing facilities in Shenzhen, China. Alltracel was founded in 1996 and listed on London's Alternative Investment Market in July 2001.
Alltracel's has a number of patents in the areas of polysaccharide manipulation and PTFE processes and products as well as a significant collaborative R&D programme in place focussed on its markets.
In the Woundcare market m.doc(TM) (Micro Dispersed Oxidized Cellulose; (www.m-doc.com)) is the trading name given to Alltracel's patented technology which is proven as an effective and efficient haemostatic (blood-stopping) agent.
- In the consumer Woundcare sector m.doc(TM) is currently being marketed as the leading stops bleeding ingredient brand within recognized woundcare, and relevant first-aid brands worldwide.
- Alltracel's woundcare technology is also currently poised for entry into the professional Woundcare and specialist Oralcare markets.
Within the Cardiovascular Health market Alltracel (www.alltracelcvh.com) has developed a novel bioactive compound that, following two years of scientific research including in vitro, pre-clinical and clinical trials, indicates cardiovascular health (CVH) benefits on its own and in combination with existing CVH products.
Alltracel's patented process utilises a derivative of cellulose fibre to produce a bioactive with scientifically proven properties that aid CVH; specifically lowering LDL cholesterol, reducing blood glucose levels and helping to prevent arterial plaque build up.
The end result is a pioneering, value-adding bioactive that can enhance and differentiate current cardiovascular health products and that can add benefit to current non-health benefiting nutritious finished foods.
- Further efficacy, dosage, timing/phasing and combination (with other bio-actives) studies to determine optimum delivery systems, formats and combinations in both the functional foods and pharmaceutical markets are underway.
- Development discussions with potential partners in the functional foods and pharmaceutical sectors in the EU, Asia and North America have commenced.
m.doc(TM) is a trademark of Alltracel Pharmaceuticals PLC. For Further Information Contact: Dublin: Kathy Wray Alltracel: +353-1-235-2162, press@alltracel.com London: Sarah MacLeod Financial Dynamics: +44-207-831-3113 New York: Sean Leous Financial Dynamics: +1-212-850-5626
Alltracel Pharmaceuticals Plc.CONTACT: Dublin: Kathy Wray, Alltracel: +353-1-235-2162,press@alltracel.com. London: Sarah MacLeod, Financial Dynamics:+44-207-831-3113. New York: Sean Leous, Financial Dynamics: +1-212-850-5626
